通过合理的联合策略克服B-ALL对靶向和免疫治疗的耐药性。

IF 11.5 Q1 HEMATOLOGY

Blood Cancer Discovery Pub Date : 2025-04-27 DOI:10.1158/2643-3230.BCD-25-0036

Miguel Quijada-Álamo, Grace Freed, Elvin Wagenblast

引用次数: 0

摘要

尽管靶向治疗和免疫治疗对b细胞急性淋巴细胞白血病（B-ALL）疗效显著，但复发和难治性病例仍然是一个主要挑战。在这篇综述中，我们讨论了如何将靶向药物与免疫治疗相结合，以帮助克服B-ALL的耐药性并改善患者的长期预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Overcoming B-ALL Resistance to Targeted and Immune Therapies by Rational Combination Strategies.

Despite the remarkable efficacy of targeted therapies and immunotherapies in B-cell acute lymphoblastic leukemia (B-ALL), relapsed and refractory cases remain a major challenge. In this review, we discuss how integrating targeted agents with immunotherapy could help overcome resistance and improve long-term patient outcomes in B-ALL.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Blood Cancer Discovery Multiple-

CiteScore

12.70

自引率

1.80%

发文量

139

期刊介绍： The journal Blood Cancer Discovery publishes high-quality Research Articles and Briefs that focus on major advances in basic, translational, and clinical research of leukemia, lymphoma, myeloma, and associated diseases. The topics covered include molecular and cellular features of pathogenesis, therapy response and relapse, transcriptional circuits, stem cells, differentiation, microenvironment, metabolism, immunity, mutagenesis, and clonal evolution. These subjects are investigated in both animal disease models and high-dimensional clinical data landscapes. The journal also welcomes submissions on new pharmacological, biological, and living cell therapies, as well as new diagnostic tools. They are interested in prognostic, diagnostic, and pharmacodynamic biomarkers, and computational and machine learning approaches to personalized medicine. The scope of submissions ranges from preclinical proof of concept to clinical trials and real-world evidence. Blood Cancer Discovery serves as a forum for diverse ideas that shape future research directions in hematooncology. In addition to Research Articles and Briefs, the journal also publishes Reviews, Perspectives, and Commentaries on topics of broad interest in the field.